Generalizing the per-protocol treatment effect: The case of ACTG A5095
Lu H, Cole S, Hall H, Schisterman E, Breger T, Edwards J, Westreich D. Generalizing the per-protocol treatment effect: The case of ACTG A5095. Clinical Trials 2018, 16: 52-62. PMID: 30326736, PMCID: PMC6693502, DOI: 10.1177/1740774518806311.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsClinical ProtocolsFemaleHIV InfectionsHumansIntention to Treat AnalysisMaleMiddle AgedSustained Virologic ResponseViral LoadConceptsFour-drug antiretroviral regimenThree-drug regimenConventional intentionAntiretroviral regimenVirologic failureTreat comparisonProtocol deviationsRisk differenceTarget populationTreatment assignmentThree-drug armInverse probability weightsACTG A5095Protocol effectUS HIVHazard ratioRandomized trialsInverse oddsTreatment protocolRegimenUS individualsHIVProtocol estimatesTrialsProtocol analysis